Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 12/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 11/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092104 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL30365037 | 0.99 | MAPK14 (0.97) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL1752996 | 0.84 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DADORA2AADORA1 | |
| SCHEMBL1753071 | 0.84 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DADORA2AADORA1 | |
| SCHEMBL16092111 | 0.82 | MAPK14 (0.69) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL16092113 | 0.80 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DADORA2AADORA1 | |
| SCHEMBL17728200 | 0.80 | MAPK11 (0.66) | MAPK14MAPK11CSNK1D | |
| SCHEMBL6515131 | 0.79 | MAPK14 (0.65) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL5847752 | 0.79 | MAPK14 (0.65) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL16061090 | 0.79 | MAPK14 (0.65) | MAPK14MAPK11CSNK1DMAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842424-B1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | UNIV COLUMBIA (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.